Sisplatin etkileşimleri
Sisplatin (Platinol) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 21 belgelenmiş etkileşim var: 6 majör, 7 orta, 8 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.
Etikete göre etkileşimler
Majör etkileşimler (6)
- BleomisinMajör
Fatal bleomycin pulmonary toxicity has been reported in a patient with unrecognized cisplatin-induced oliguric renal failure. (Bleomisin etiketi, İlaç etkileşimleri)
…magnesium hydroxide Prevention or Management: Phenytoin and antacids should not be taken at the same time of day Antineoplastic agents (usually in combination) Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam, diazoxide,… (Fenitoin etiketi, İlaç etkileşimleri)
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (Gentamisin etiketi, Kutulu uyarı)
Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (Neomisin etiketi, Kutulu uyarı)
Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (Pentamidin etiketi, İlaç etkileşimleri)
- SorafenibMajör
NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (Sorafenib etiketi, Uyarılar ve önlemler)
Orta düzey etkileşimler (7)
…phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam, diazoxide,… (Fosfenitoin etiketi, İlaç etkileşimleri)
• Cisplatin and nephrotoxic drugs : Risk of ototoxicity and nephrotoxicity ( 7.1 ) (Furosemid etiketi, İlaç etkileşimleri)
- İfosfamidOrta
Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use. (İfosfamid etiketi, Uyarılar ve önlemler)
Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. (Rituksimab etiketi, Uyarılar ve önlemler)
The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (Takrolimus etiketi, Uyarılar ve önlemler)
- TrilasiklibOrta
Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin) [see Clinical Pharmacology ( 12.3 )]. (Trilasiklib etiketi, İlaç etkileşimleri)
The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. (Verapamil etiketi, İlaç etkileşimleri)
Minör değinmeler (8)
Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)
- DosetakselMinör
In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (Dosetaksel etiketi, Uyarılar ve önlemler)
- MelfalanMinör
Cisplatin may affect melphalan kinetics by inducing renal dysfunction and subsequently altering melphalan clearance. (Melfalan etiketi, İlaç etkileşimleri)
Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. (Ondansetron etiketi, İlaç etkileşimleri)
…(38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B 12 prior to and throughout pemetrexed plus cisplatin treatment. (Pemetrekset etiketi, Uyarılar ve önlemler)
Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (Spironolakton etiketi, Uyarılar ve önlemler)
Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (Torasemid etiketi, Uyarılar ve önlemler)
- VinorelbinMinör
Myelosuppression Myelosuppression, manifested by neutropenia, anemia and thrombocytopenia, occur in patients receiving vinorelbine as a single agent and in combination with cisplatin [see Adverse Reactions ( 6.1 , 6.2 )] . (Vinorelbin etiketi, Uyarılar ve önlemler)
Kullandığınız her şeyi Sisplatin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.
Sorgulama aracında açTıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.